Science Exchange--which runs an outsourcing business service for biopharma and smaller life science groups--has raised $25 million in a new Series B funding…

Moderna Therapeutics, a high-profile private biotech with scores of preclinical projects, is finally moving toward human trials, recruiting one of the world…

WuXi PharmaTech, China's largest CRO, closed an oversubscribed $290 million venture fund, turning its attention to biopharma startups at home and in…

The head of the U.K.'s Trade & Investment in the Ministry of the same name has begun a three-day visit to India to focus on biotech and health…

China biotech Innovent's recent success in raising $100 million in venture capital to help it build a pipeline of biosimilars could be a signal of how…

LabCorp is diversifying. The big diagnostics player has swooped in to buy the contract research organization Covance for $6.1 billion in cash and stock,…

The private equity group announced this morning that it will buy out Medpace, continuing an M&A trend that has spurred a sizable shakeout of the CRO…

Avillion has scored one of its first risk-sharing deals on a late-stage pharma asset, striking a deal to do a Phase III study of Pfizer's Bosulif (…

The Cranbury, NJ-based biotech says they will focus on knockoffs ofHumira, Rituxan, Avastin, Herceptin and Erbitux.

Outsourcing